66 Results for "

CHK1 kinase

" in MedChemExpress (MCE) Product Catalog:
Products (66)

66 Results for "CHK1 kinase" in MCE Product Catalog:

39
39 Publications Verification
Cat. No.: HY-18174
CAS No.: 1234015-52-1
Synonyms: LY2606368
Research Areas:  

Cancer

Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity .
loading...
    loading...
39
39 Publications Verification
Cat. No.: HY-18174A
CAS No.: 1234015-54-3
Synonyms: LY2606368 dihydrochloride
Research Areas:  

Cancer

Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity .
loading...
    loading...
39
39 Publications Verification
Cat. No.: HY-18174E
CAS No.: 1234015-58-7
Synonyms: LY2606368 dimesylate
Research Areas:  

Cancer

Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity .
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-10992
CAS No.: 860352-01-8
Purity:  99.94%
Research Areas:  

Cancer

AZD-7762 is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC50 of 5 nM for Chk1.
loading...
    loading...
26
26 Cited Publications
Cat. No.: HY-10992A
CAS No.: 1246094-78-9
Purity:  98.03%
Research Areas:  

Cancer

AZD-7762 hydrochloride is a potent ATP-competitive checkpoint kinase (Chk) inhibitor in with an IC50 of 5 nM for Chk1.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15532
CAS No.: 891494-63-6
Purity:  99.81%
Synonyms: MK-8776
Research Areas:  

Cancer

SCH900776 (MK-8776) is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with an IC50 of 3 nM. SCH900776 shows 50- and 500-fold selectivity over CDK2 and Chk2, respectively .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-136270
CAS No.: 1613191-99-3
Purity:  99.77%
Synonyms: VX-803; M4344; ATR inhibitor 2
Target:  

ATM/ATR

Research Areas:  

Cancer

Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of <150 pM. Gartisertib potently inhibits ATR-driven phosphorylated checkpoint kinase-1 (Chk1) phosphorylation with an IC50 of 8 nM. Antitumor activity .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-107407
CAS No.: 135897-06-2
Purity:  98.30%
Research Areas:  

Cancer

SB-218078 is a potent, selective, ATP-competitive and cell-permeable checkpoint kinase 1 (Chk1) inhibitor that inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM. SB-218078 is less potently inhibits Cdc2 (IC50 of 250 nM) and PKC (IC50 of 1000 nM). SB-218078 causes apoptosis by DNA damage and cell cycle arrest .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P80082
Synonyms: CHK1, CHEK1, Serine/threonine-protein kinase CHK1, CHK1 checkpoint homolog, Cell cycle checkpoint kinase, Checkpoint kinase-1

Host:  

Rabbit

Application:  

WB, ICC/IF, IHC-P, FC

Reactivity:  

Human, Mouse

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-114302
CAS No.: 2100864-57-9
Purity:  99.89%
Target:  

Microtubule/Tubulin

Research Areas:  

Cancer

CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC50 of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-131446
CAS No.: 2120398-39-0
Research Areas:  

Cancer

Chk1-IN-5 is a potent checkpoint kinase 1 (Chk1) inhibitor. Chk1-IN-5 inhibits Chk1 phosphorylation and inhibits tumor growth in colon cancer xenograft model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P80455
Synonyms: CHK1, CHEK1, Serine/threonine-protein kinase CHK1, CHK1 checkpoint homolog, Cell cycle checkpoint kinase, Checkpoint kinase-1

Host:  

Rabbit

Application:  

WB, IHC-P

Reactivity:  

Human

loading...
    loading...
Cat. No.: HY-157941
CAS No.: 2267316-76-5
Purity:  99.89%
Synonyms: ART0380
Research Areas:  

Cancer

ART0380 is a potent, selective and orally active ATR kinase inhibitor. ART0380 potently inhibits human ATR-ATRIP complex with an IC50 of 51.7 nM. ART0380 binds the ATP pocket of the ATR-ATRIP complex, blocks ATR-dependent Chk1 serine 345 phosphorylation, and induces cell cycle disorder and DNA damage. ART0380 demonstrates potent and selective antitumor activity in preclinical models with varying types of ataxia-telangiectasia mutated (ATM) gene aberrancy. ART0380 can be used for the research of cancer, such as colorectal cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-15532B
CAS No.: 891494-64-7
Purity:  99.28%
Synonyms: MK-8776 S-isomer
Target:  

Drug Isomer

Research Areas:  

Cancer

SCH900776 S-isomer is the S-isomer of SCH900776. SCH900776 is a potent, selective and orally bioavailable inhibitor of checkpoint kinase1 (Chk1) with IC50 of 3 nM.
loading...
    loading...
Cat. No.: HY-18961
CAS No.: 622864-54-4
PD 407824 is a checkpoint kinase Chk1 and WEE1 inhibitor with IC50s of 47 and 97 nM, respectively. PD 407824 is a chemical BMP sensitizer and increases the sensitivity of cells to sub-threshold amounts of BMP4 .
loading...
    loading...
Cat. No.: HY-19926
CAS No.: 1200129-48-1
Synonyms: RG-7602
Research Areas:  

Cancer

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies .
loading...
    loading...
Cat. No.: HY-157764
CAS No.: 2925916-30-7
Research Areas:  

Cancer

PROTAC ATR degrader-1 is a ATR PROTAC degrader. PROTAC ATR degrader-1 promotes ubiquitination and degradation of ATR. PROTAC ATR degrader-1 facilitates the progression of cells through the G2/M phase, thereby impairing DNA repair and inducing Apoptosis. PROTAC ATR degrader-1 exerts anticancer effects against colorectal cancer either alone or in combination with Cisplatin (HY-17394). PROTAC ATR degrader-1 can be used in research related to colorectal cancer .
loading...
    loading...
Cat. No.: HY-16129
CAS No.: 565434-85-7
CBP-501, a cell-permeable calmodulin-binding peptide and a G2-abrogating drug candidate, inhibits the activity of multiple Ser 216-specific kinases, such as MAPKAP-K2, C-Tak1, CHK1 and CHK2, with IC50 values of 0.9 μM, 1.4 μM 3.4 μM and 6.5 μM, respectively. CBP-501 is used for various types of cancer .
loading...
    loading...
Cat. No.: HY-128601
CAS No.: 2097252-39-4
Purity:  99.79%
Research Areas:  

Cardiovascular Disease Cancer

CHK1-IN-3 is a potent and selective CHK1 inhibitor with an IC50 of 0.4 nM. CHK1-IN-3 effectively inhibits the growth of malignant hematopathy cell lines and displays low affinity for hERG (IC50 > 40 μM). CHK1-IN-3 significantly suppresses the tumor growth in vivo. CHK1-IN-3 can be used for the study of hematologic malignancies .
loading...
    loading...
Cat. No.: HY-157767
CAS No.: 3021581-79-0
Research Areas:  

Cancer

Abd110 is a selective ATR PROTAC degrader. Abd110 recruits Cereblon to induce the proteasomal degradation of ATR, and reduces the levels of phosphorylated ATR and downstream phosphorylated CHK1. Abd110 can be used for research on pancreatic cancer and cervical cancer .
loading...
    loading...